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The importance of coordinating cell growth with proliferation has been recognized for a long time. The
molecular basis of this relationship, however, is poorly understood. Here we show that the ribosomal protein
L23 interacts with HDM2. The interaction involves the central acidic domain of HDM2 and an N-terminal
domain of L23. L23 and L11, another HDM2-interacting ribosomal protein, can simultaneously yet distinctly
interact with HDM2 together to form a ternary complex. We show that, when overexpressed, L23 inhibits
HDM2-induced p53 polyubiquitination and degradation and causes a p53-dependent cell cycle arrest. On the
other hand, knocking down L23 causes nucleolar stress and triggers translocation of B23 from the nucleolus
to the nucleoplasm, leading to stabilization and activation of p53. Our data suggest that cells may maintain a
steady-state level of L23 during normal growth; alternating the levels of L23 in response to changing growth
conditions could impinge on the HDM2-p53 pathway by interrupting the integrity of the nucleolus.
The tumor suppressor protein p53 plays a pivotal role in
preventing damaged and abnormal cells from becoming ma-
lignant, and its loss of function is associated with a majority of
human cancers (26, 36, 37). The activity of p53 is not required
for normal cell growth, and the protein is kept at low levels
and inactive. This is accomplished by the proto-oncoprotein
HDM2 (human counterpart of MDM2 in mice) through either
ubiquitin-dependent p53 degradation in the cytoplasm (6, 7,
11) or repression of p53 transcriptional activity in the nucleus
(17, 35). The HDM2 gene can, in turn, be transcriptionally
activated by p53, constituting a feedback regulatory loop (1,
40). The current understanding of the major mechanisms of
p53 activation includes one that is triggered by DNA damage
and induces p53 phosphorylation through a cascade of protein
kinases (5, 15, 32) and one that is triggered by aberrant onco-
genic signals and is mediated by p14ARF (p19ARF in mice) (31).
Little is known about the connection between p53 and ribo-
somal biogenesis, even though ribosomal biogenesis occupies
the major part of a cell’s life cycle. Whether and how p53 may
be involved in checking ribosomal stress and the integrity of
ribosomal biogenesis remains elusive (28).
Previous studies have identified the interaction of the ribo-
somal protein L5 with HDM2 (14). Recently, it has been
shown that the ribosomal protein L11 also interacts with
HDM2, and through this interaction, L11 stabilizes and acti-
vates p53 and induces a cell cycle arrest (13, 41). This is
achieved, at least in part, through L11 inhibiting the E3 ligase
activity of HDM2 (41). Based on the evidence that low levels
of actinomycin D, which selectively inhibits rRNA transcrip-
tion, enhances L11-HDM2 interaction, it has been proposed
that L11 plays a role in the response to ribosomal perturba-
tions to induce p53 and cell cycle arrest. In this study, we
describe functional interactions of HDM2 with L23, a protein
component in the 60S large ribosomal subunit. The interaction
of HDM2 with L23 involves a domain in HDM2 that is distinct
from that required for L11 binding, and L23 and L11 can
simultaneously bind with HDM2 to form a ternary complex.
Our data indicate that L23 reacts to inhibitions of rRNA bio-
genesis distinctively from that of L11 and suggest that multiple
ribosomal proteins interact with HDM2 and that each may play
a different role in regulating the HDM2-p53 pathway in re-
sponse to perturbations of protein or ribosomal biogenesis.
MATERIALS AND METHODS
Plasmids and cell culture. Mutant HDM2 and L23 constructs were generated
by PCR-mediated site-directed mutagenesis and confirmed by direct sequencing.
U2OS, Saos2, and SJSA cells were obtained from the American Type Culture
Collection. WI38 cells (PD 25) and E6 retroviruses were from Judith Campisi
(Lawrence Berkeley National Laboratory, Berkeley, Calif.). All cells were rou-
tinely maintained in Dulbecco’s modified Eagle medium containing 10% fetal
bovine serum in a 37°C incubator with CO2.
Immunoprecipitation, immunoblotting, and immunostaining. Mouse mono-
clonal antibody to HDM2 (Ab-1; Oncogene Research Products), goat polyclonal
antibody to human p53 (FL393; Santa Cruz), and mouse monoclonal antibody to
human p53 (DO-1; NeoMarkers) were purchased commercially. Rabbit poly-
clonal antibody to human L23 was produced by a synthetic peptide based on a
DNA sequence corresponding to amino acid residues 81 to 96 of human L23
(VIRQRKSYRRKDGVFL). Procedures and conditions for immunoprecipita-
tion, immunoblotting, and immunostaining were previously described (9).
Ad and retrovirus infections. Adenovirus (Ad) expressing human L23 was
produced by subcloning full-length L23 into the vector pShuttle, and recombi-
nant Ad was produced by overlap recombination. Sources of Ad expressing
human p53, HDM2, and human ARF and procedures for Ad infection were
described elsewhere (42, 44). E6 retroviruses were infected in WI38 cells and
selected as previously described (10).
Cell transfection and fluorescence-activated cell sorter analysis. Cell trans-
fections were carried out by using either Effectene or Lipofectamine reagents
(Invitrogen, Carlsbad, Calif.) according to the manufacturer’s instructions. For
fluorescence-activated cell sorter analysis, cells were cotransfected with the in-
dicated plasmid DNA, harvested by trypsinization, fixed in 70% ethanol, and
stained with propidium iodide (50 g/ml) containing 50 g of RNase A/ml. Flow
cytometry analysis was conducted by using a Becton Dickinson FACScan. Green
fluorescent protein (GFP) was used as a marker for analysis of transfected cells.
Results for DNA content from at least 20,000 cells are presented in the DNA
histograms.
siRNA interference. Purified and annealed duplex small interfering RNA
(siRNA) oligonucleotides targeting nucleotides 147 to 168 relative to the trans-
lation initiation codon of human L23, siRNA oligonucleotides targeting nucle-
otides 363 to 383 relative to the translation initiation codon of human L11, and
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control scrambled siRNA oligonucleotides were synthesized at Dharmacon
(Lafayette, Colo.). Transfection was performed by using Lipofectamine and Plus
reagents (Invitrogen) according to the manufacturer’s instructions.
Indirect immunofluorescence. Indirect immunofluorescence was previously
described in detail (43). Antibodies to human p53 and HDM2 were previously
described (42). Texas Red- and fluorescein isothiocyanate-conjugated secondary
antibodies (Jackson ImmunoResearch Laboratories) were purchased commer-
cially.
RESULTS
L23 interacts with HDM2. It was noticed in a previous study
that a number of low-molecular-weight polypeptides were
present in an HDM2 immunocomplex and that the presence of
these polypeptides is independent of the interaction of HDM2
with ARF and/or p53 (44). To identify the nature of these
HDM2-interacting polypeptides, we carried out large-scale co-
immunoprecipitation (co-IP) and mass spectrometry experi-
ments. Utilizing Ad-mediated overexpression of HDM2 and
co-IP with an antibody (4B11) specific to the HDM2 protein, a
number of polypeptides were detected only in the HDM2 im-
munocomplex, but not in the control sample infected with Ad
expressing GFP (Ad-GFP) (Fig. 1A). The three most promi-
nent bands on the silver-stained gel were subjected to mass
spectrometry analysis. They were identified as ribosomal pro-
teins L5 (34 kDa), L11 (20 kDa), and L23 (15 kDa), all of
which are peptide components associated with the 60S large
ribosomal subunit. The interaction of HDM2 with L5 (14) and
L11 (13, 41) has been previously reported; the interaction of
HDM2 with L23 has not been shown. Full-length L23, 140
amino acid residues with a calculated molecular mass of 14,865
Da (EMBL accession number X55954), was obtained by re-
verse transcription-PCR from a HeLa cell cDNA library. Poly-
clonal antibodies against a short peptide (VIRQRKSYRRKD
GVFL) from L23 were raised. The in vivo interaction of
HDM2 and L23 was confirmed by co-IP with ectopically ex-
pressed HDM2 and L23 (Fig. 1B) and by reciprocal co-IP with
endogenous proteins at physiological conditions with SJSA
cells (ATCC CRL-2098), which express a relatively high level
of HDM2 (Fig. 1C).
To determine the domains in HDM2 involved in the L23
interaction, we constructed deletion mutants of the HDM2
protein and tested their binding activity to L23 in transiently
transfected U2OS cells (Fig. 2A). Our results mapped a se-
quence between amino acids 216 and 284 in HDM2 that is
required for L23 binding. A deletion mutant of HDM2 con-
FIG. 1. HDM2 interacts with ribosomal protein L23. (A) Mass spectrometry identification of HDM2 binding proteins. Extracts of U2OS cells
infected with the indicated Ad for 2 days were immunoprecipitated with HDM2 antibody 4B11 and were resolved on a silver-stained gel (SDS–
12.5% PAGE). Three ribosomal proteins, L5, L11, and L23, were identified based on peptide sequences obtained from the mass spectrometry.
HDM2, anti-HDM2; IgG, immunoglobulin G; K, thousands. (B) Binding between ectopically expressed HDM2 and L23. HeLa cells were
transfected with indicated plasmid DNA for 24 h. Each cell extract was immunoprecipitated (IP) with antibodies to either HDM2 (4B11, left panel)
or myc (9E10, right panel), and the precipitates were resolved by SDS-PAGE, transferred onto a nitrocellulose membrane, and blotted with
antibodies to HDM2 (N20; Santa Cruz) and myc (A14; Santa Cruz). myc, anti-myc; , present; , absent. (C) Binding between endogenous
HDM2 and L23. Endogenous HDM2 and L23 binding was detected by coIP from SJSA cells with antibodies to HDM2 (4B11) and L23, and
Western blotting (WB) was performed as described above. Saos2 cells were served as a negative control. L23, anti-L23.
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FIG. 2. Mapping of the HDM2 domain for L23 binding and the L23 domain for HDM2 binding. (A) Mapping of the HDM2 domain for L23
binding. Extracts from U2OS cells transfected with the indicated plasmid DNA encoding deletion mutants of HDM2 were immunoprecipitated
with HDM2 antibodies (4B11 for lanes 1, 6, and 7; SMP14 for lane 2; 2A10 for lanes 3 and 5), and the precipitates were resolved by SDS-PAGE,
transferred to a nitrocellulose membrane, and blotted with a mixture of two rabbit anti-HDM2 (-HDM2) antibodies (N20 and H228; Santa Cruz).
A diagram of each deletion mutant is shown. WT, wild type; -myc, anti-myc; WB, Western blotting; , present; , absent. (B) Mapping of the
L23 domain for HDM2 binding. Extracts from U2OS cells transfected with the indicated plasmid DNA encoding deletion mutants of L23 were
immunoprecipitated with HDM2 antibody 4B11, and the precipitates were resolved by SDS-PAGE, transferred to a nitrocellulose membrane, and
blotted with antibodies to HDM2 (N20) and myc (A14) as indicated. A diagram for the deletion mutants is shown.
VOL. 24, 2004 INHIBITION OF HDM2 AND ACTIVATION OF p53 BY L23 7671
taining sequences from amino acids 284 to 491 (the C terminus
of HDM2) also appeared to have a weak binding activity,
suggesting that other sequences in HDM2 downstream of
amino acid 284 also contribute to L23 binding (Fig. 2A, lane 7).
The deletion mutants containing the C terminus (amino acids
216 to 491 and 284 to 491) (lanes 6, 7, 13, and 14) or the middle
part (amino acids 216 to 374) (lanes 5 and 12) of HDM2
migrated slightly slower on the sodium dodecyl sulfate-polyac-
rylamide gel electrophoresis (SDS-PAGE) gel than they were
supposed to according to their calculated sizes. The reason for
this slow migration is not clear. Notably, the L23 binding do-
main in HDM2 (amino acids 216 to 284) appears to overlap
with the sequences required for ARF binding (amino acids 212
to 244 in HDM2) (16). Whether L23 and ARF antagonize each
other for HDM2 binding remains to be determined. We also
mapped the sequences in L23 that are required for HDM2
binding. Our results showed that a short stretch of amino acids
between positions 43 and 70 in L23 was necessary for HDM2
interaction (Fig. 2B).
L23 and L11 simultaneously interact with HDM2 to form a
ternary complex. Recent studies have shown that the ribo-
somal protein L11 interacts with HDM2, and the L11-binding
site on HDM2 was mapped at amino acids 212 to 347 in one
study (13) and at amino acids 284 to 374 in another study (41).
Our data indicate that the major site in HDM2 for L23 binding
is between amino acids 216 and 284. Thus, the HDM2 binding
sites for L11 and L23 appear to be nonoverlapping, and there-
fore, it is possible that L11 and L23 can bind with HDM2
simultaneously to form ternary complexes. To determine
whether L23 and L11 can bind HDM2 simultaneously to form
a multi-ribosomal-protein–HDM2 complex or, alternatively,
whether the two ribosomal proteins may compete with each
other for HDM2 binding, we carried out co-IP to test the
possibility of a complex formation among HDM2, L11, and
L23. Endogenous L23 was immunoprecipitated with an anti-
L23 antibody from U2OS cells infected with Ad-HDM2 and
blotted with antibodies to HDM2, L23, and L11, respectively.
As shown in Fig. 3, when precipitated with an L23 antibody,
L11 was detected only in the presence of HDM2 but not in the
control cell lysate lacking overexpressed HDM2, indicating
that (i) L23 does not directly interact with L11 even though
they are both components of the 60S large ribosomal subunit
and both exist abundantly in cells and (ii) HDM2 is able to
interact with both L11 and L23 simultaneously to form a ter-
nary complex.
Overexpression of L23 inhibits HDM2-mediated p53 polyu-
biquitination and degradation and induces a p53-dependent
cell cycle arrest. To investigate the functional consequences of
L23-HDM2 interaction, we examined whether L23 could affect
the function of HDM2 in degrading p53. Plasmid DNA ex-
pressing HDM2, p53, and myc-tagged L23 were used to trans-
fect U2OS cells, and the steady-state levels of each protein
were determined by Western blotting. As shown in Fig. 4A,
cotransfection of plasmid DNA expressing myc-L23 restored
the level of p53 that had been reduced by HDM2 (compare
lanes 3 and 4), indicating that L23, like two other HDM2-
binding proteins, ARF and L11, can inhibit HDM2-mediated
p53 degradation. Similar inhibition of HDM2-mediated p53
degradation was also observed in normal human fibroblast
WI38 cells infected with Ad expressing a myc-tagged L23 (Ad-
myc-L23) (Fig. 4B). L23 overexpression not only stabilized p53
but also stabilized HDM2—a self-ubiquitinated fast-turnover
protein. The ability of L23 to inhibit HDM2-induced p53 deg-
radation could be explained, at least in part, by its ability to
inhibit HDM2-mediated p53 polyubiquitination (Fig. 4C). The
ability of L23 to inhibit HDM2’s E3 ligase function appeared
to be at a level comparable to that of ARF and L11 (Fig. 4C,
compare lane 3 with lanes 4 and 5). To distinguish whether the
increased HDM2 level is from p53 activation or from L23-
inhibited HDM2 degradation, we established a WI38 deriva-
tive cell line, WI38-E6, in which p53 is under negative regula-
tion by the oncogene E6 of the human papillomavirus. The
product of the E6 gene targets p53 by inducing its degradation
by the ubiquitin proteolytic pathway (30). As shown in Fig. 4D,
when the WI38-E6 cells were singly infected with Ad-HDM2
or doubly infected with Ad-myc-L23 and Ad-HDM2, the
HDM2 level was significantly higher in the double infection,
indicating that L23 stabilizes HDM2 in the absence of p53.
To determine whether the L23-stabilized p53, in the pres-
ence of an elevated level of HDM2, is transcriptionally active,
we infected WI38 cells with Ad-myc-L23 and determined the
endogenous level of p53 as well as the endogenous levels of
HDM2 and p21—two proteins whose genes can be transacti-
vated by p53. In cells infected with Ad-myc-L23, the levels of
p53, HDM2, and p21 were all increased, whereas, by compar-
ison, p21 and HDM2 were not increased in Ad-myc-L23-in-
fected WI38-E6 cells, indicating that this function of L23 to
induce HDM2 and p21 is dependent on its ability to activate
p53 (Fig. 5A and B). The activation of p53 by L23 was also
determined by analysis of cell cycle distributions in WI38 and
WI38-E6 cells infected with Ad-myc-L23. As expected, L23
induced cell cycle arrest only in WI38, but not in WI38-E6,
cells (Fig. 5C and D).
To examine the cellular localization of L23-HDM2 interac-
tion, we infected U2OS cells with Ad-myc-L23 and examined
the localization of myc-L23 and endogenous HDM2 by immu-
nofluorescence staining. As shown in Fig. 5E, in cells express-
ing myc-L23, HDM2 was detected primarily in the nucleo-
plasm but also was visible in the cytoplasm. myc-L23, on the
FIG. 3. L23 and L11 simultaneously interact with HDM2 to form
ternary complexes. Extracts from U2OS cells infected with Ad express-
ing HDM2 for 2 days were immunoprecipitated (IP) with L23 anti-
bodies, and Western blotting (WB) was performed with antibodies to
HDM2 (4B11), L11, and L23. Endog, endogenous; -L23, anti-L23;
-L11, anti-L11; -HDM2, anti-HDM2.
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other hand, was seen highly concentrated in the nucleolus, with
a clear accumulation in the nucleoplasm, and to a lower extent
in the cytoplasm. Thus, the interaction between L23 and HDM2
could occur in both the nucleus and the cytoplasm. Together,
our data show that overexpression of L23 leads to inhibition of
HDM2-mediated p53 polyubiquitination, increased protein
levels of both HDM2 and p53, and an increased transactivation
activity of p53 and induces a cell cycle arrest.
Knocking down L23, but not L11, activates p53 and induces
cell cycle arrest. To examine the effect of down-regulation of
L23 on the function of HDM2 and p53, we carried out an RNA
interference experiment to knock down endogenous L23 in
U2OS cells and examined the endogenous protein level and
the transcriptional activity of p53 by both Western blotting and
cell cycle analysis. When L23 was knocked down to approxi-
mately half of its original level, there was a moderate but
FIG. 4. L23 inhibits HDM2-mediated p53 polyubiquitination and degradation. (A) Ectopic expression of L23 stabilizes HDM2 and p53. U2OS
cells were transfected with the indicated plasmid DNA for 2 days, and cell extracts were resolved by SDS-PAGE, transferred onto a nitrocellulose
membrane, and blotted with antibodies as indicated. Plasmid DNA expressing GFP was cotransfected as a control. , present; , absent; -HDM2,
anti-HDM2; -p53, anti-p53; -myc, anti-myc; -GFP, anti-GFP. (B) Ectopic expression of L23 stabilizes HDM2 and p53 in normal human
fibroblast cells. WI38 cells were infected with virus expressing HDM2 for 2 days, and cell extracts were resolved by SDS-PAGE, transferred onto
a nitrocellulose membrane, and blotted with antibodies as indicated. Virus expressing GFP was coinfected as a control. -actin, anti-actin. (C) L23
inhibits HDM2-mediated p53 polyubiquitination. U2OS cells were transfected with the indicated plasmid DNA for 2 days, and the cells were
treated with MG132 (25 M) for 5 h before lysing. Cell extracts were analyzed by Western blotting with antibodies to p53 (D01) and myc (9E10)
as indicated. (D) L23 stabilizes HDM2 independent of p53. WI38-E6 cells were infected with viruses expressing GFP, HDM2, and myc-L23 as
indicated. Cells were lysed 2 days after infection, and the cell lysates were blotted as described above. Endog, endogenous; -L23, anti-L23.
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FIG. 5. L23 induces a p53-dependent cell cycle arrest. (A and B) L23 overexpression stabilizes and activates p53. Normal human fibroblast
WI38 cells and isogenic mutant WI38-E6 cells were infected with the indicated Ad for 2 days. Western blotting was performed as described above.
-myc, anti-myc; -HDM2, anti-HDM2; -p53, anti-p53; -p21, anti-p21; -actin, anti-actin. (C and D) L23 induces a p53-dependent cell cycle
arrest. WI38 and WI38-E6 cells were infected with the indicated viruses. Cells were harvested 2 days after infection, fixed with 70% ethanol for
2 h, and stained with propidium iodide for 1 h, and the cell cycle distribution was determined by flow cytometry. Cell populations in the S phase
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reproducible increase of the protein levels of p53 (Fig. 6A, lane
3). Accompanied by an increased p53 protein level, its tran-
scriptional activity was also increased, as shown by the in-
creased protein levels of HDM2 and p21, the downstream
targets of p53’s transcriptional function (Fig. 6A). In contrast,
however, knocking down L11 to approximately half of its orig-
inal level did not increase the protein level or the transactiva-
tion activity of p53, but rather it appeared to decrease the level
of p53 (Fig. 6B). Thus, L23 and L11 apparently employ differ-
ent mechanisms in regulating HDM2-p53 function. Consistent
with the Western blotting results, knocking down L23 also
induced a cell cycle arrest in U2OS cells (Fig. 6C), whereas
knocking down L11 did not apparently affect the cell cycle
distribution (Fig. 6D).
To determine whether the cell cycle arrest by down-regula-
tion of L23 was dependent on the function of p53, we chose to
use the normal human fibroblast WI38 cells and their p53-
deficient derivatives, WI38-E6 cells, to perform the knocking
down experiments. When L23 was knocked down in WI38
cells, there was a small but reproducible increase in the protein
level of p53 (Fig. 7A). In contrast to the marginal increase in
the level of p53, knocking down L23 considerably increased the
levels of HDM2 and p21, indicating an increase of the trans-
activation activity of p53. In WI38-E6 cells, knocking down L23
did not affect the level of p21, and the levels of p53 and HDM2
remained undetectable (Fig. 7B). Consistent with the activa-
tion of p53, knocking down L23 also induced cell cycle arrest in
WI38 cells but not in WI38-E6 cells (Fig. 7C and D).
To gain an insight into the mechanism by which down-reg-
ulation of L23 activates p53, we performed immunofluores-
cence staining of the nucleolar protein B23 in U2OS cells. B23
has been shown to possess multiple cellular functions, includ-
ing ribosomal protein assembly and transport (23), centrosome
duplication (22), molecular chaperone activity in preventing
protein aggregation (33), regulation of the stability and activity
of p53 (2), and an endoribonuclease activity in the processing
of the 32S rRNA precursor into 28S rRNA (9, 29). B23 dislo-
cation from the nucleolus after cellular stress has recently been
linked to p53 activation (27). We found that knocking down
L23 caused the release of B23 from the nucleolus and accu-
mulated it in the nucleoplasm (Fig. 7E). Thus, a potential
mechanism of p53 activation by down-regulation of L23 could
be to induce a nucleolar stress and to release the nucleolar B23
as well as other constituents of the nucleolus into the nucleo-
plasm, where B23 could interact with p53 to cause cell cycle
arrest (2).
Inhibition of ribosomal biogenesis down-regulates the pro-
tein level of L23. Actinomycin D has been used as a chemo-
therapeutic drug in the treatment of a variety of human can-
cers (4). At high concentrations (e.g., 30 nM), actinomycin D
causes DNA damage and inhibits transcription from all three
classes of RNA polymerase promoters, whereas at low concen-
trations (e.g., 10 nM), actinomycin D does not cause DNA
damage but selectively inhibits RNA polymerase I-dependent
transcription and, therefore, rRNA biogenesis (8, 24). To ex-
amine whether inhibition of rRNA biogenesis by actinomycin
D may affect the level and/or localization of L23, we first
determined the minimal dosage of actinomycin D that is able
to induce p53 in U2OS cells. When U2OS cells were treated
with an increasing amount of actinomycin D for 24 h, endog-
enous p53 was stabilized and activated at a concentration as
low as 1.2 nM (Fig. 8A). Surprisingly, we also noticed a clear
decrease in endogenous L23 when the cells were treated with
actinomycin D, and the decrease is in an inverse correlation
with the increase in p53. We further determined the incubation
time of actinomycin D with cells that could cause the decrease
of L23. At 5 nM, actinomycin D caused a significant decrease
in L23 by 24 h of incubation but did not have much effect by 8 h
(Fig. 8B). We consider the down-regulation of L23 to not be
the consequence of cell cycle arrest, since cell cycle arrest
induced by UV irradiation or serum starvation maintained
normal levels of L23 (data not shown). Nor was it a result of
inhibition of protein synthesis, since in actinomycin D-treated
cells, p53 and HDM2 accumulated to high levels, indicating
that protein synthesis remained active (Fig. 8A, lanes 5 and 6,
and B, lanes 2 and 3).
A previous study has shown that treating cells with 5 nM
actinomycin D for 24 h did not alter the endogenous protein
level of L11 (41). To determine whether actinomycin D-in-
duced down-regulation of L23 is specific for L23, we compared
the levels of L23 and L11 under the same conditions. As shown
in Fig. 8C, only the level of L23, but not that of L11, was
decreased by actinomycin D treatment, indicating that the
down-regulation of L23 by actinomycin D treatment is a spe-
cific response of L23 and suggesting that distinct mechanisms
are employed by L11 and L23 in response to perturbations of
ribosomal biogenesis. The outcomes of down-regulating L23
by actinomycin D treatment and by siRNA are quite similar in
that, in both experiments, a decreased level of L23 is correlated
with activated p53. These results prompted us to hypothesize
that cells may have a mechanism for maintaining a constant
level of L23. Perturbations of rRNA biogenesis and/or other
types of growth inhibition may cause cell cycle arrest through
down-regulation of the level of L23, which will consequently
activate p53 function. To determine whether expression of
exogenous L23 may suppress the expression of endogenous
L23, we infected cells with Ad expressing myc-L23 and deter-
mined the level of both exogenous myc-L23 and endogenous
L23 with an anti-L23 antibody. Consistently, U2OS cells ex-
pressing myc-L23 exhibited a substantially lower level of en-
dogenous L23, indicating a repression of the expression of
endogenous L23 by ectopically expressed L23 (Fig. 8D, lane 2).
In contrast, cells expressing myc-L11 did not show a decrease
of endogenous L11 (Fig. 8D, lane 4), indicating that this is an
L23-specific reaction of the cell. The repression of endogenous
L23 by exogenous L23 was not due to a potential effect of a
are indicated as percentages of total cells. (E) L23 interacts with HDM2 in the nucleoplasm. U2OS cells were singly infected with Ad expressing
myc-L23 for 2 days. Cells were then fixed with 3% paraformaldehyde for 10 min and immunostained with a rabbit anti-myc antibody (9E10) and
a mouse anti-HDM2 antibody (N20). Nuclei were visualized by 4,6-diamidino-2-phenylindole (DAPI) staining. Fluorescence images were
captured with a cooled charge-coupled device color digital camera (model 2.2.0; Diagnostic) on an Olympus IX70 inverted microscope equipped
with the appropriate fluorescence filters.
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changed cell cycle distribution, since the reduction of endog-
enous L23 was not observed when cells were promoted into S
phase with Ad-HDM2 infection or were arrested at G1 phase
with Ad-p53 infection (Fig. 8E, lanes 3 and 5). Furthermore,
the effect of exogenous myc-L23 on the suppression of expres-
sion of endogenous L23 was not affected by coexpression of
L23 with HDM2 or with p53 (Fig. 8E, lanes 4 and 6), indicating
that the repression of endogenous L23 by exogenous L23 is
independent of the function of p53. Together, these results
suggest that a normal level of L23 is essential for maintaining
normal cell growth and proliferation.
DISCUSSION
Although recent studies have shown considerable interest in
understanding the link between ribosomal biogenesis and cell
cycle progression, the molecular mechanism that controls such
a link remains obscure (28, 34). Previous studies have identi-
fied the interaction of the ribosomal protein L5 with HDM2;
the functional significance of this interaction, however, re-
mains unclear (14). Recently, it has been shown that ribosomal
protein L11 interacts with HDM2, and through the interaction,
L11 stabilizes and activates p53 and induces a cell cycle arrest
FIG. 6. Knocking down L23, but not L11, activates p53 and induces a cell cycle arrest. (A and B) U2OS cells were either untreated (Buffer)
or transfected with a control scrambled RNA duplex (siScr), L23 siRNA (siL23), or L11 siRNA (siL11) for 2 days. Cell extracts were collected and
analyzed by Western blotting with the indicated antibodies. -HDM2, anti-HDM2; -p53, anti-p53; -p21, anti-p21; -L23, anti-L23; -actin,
anti-actin. (C and D) U2OS cells were transfected with siRNA as described for panels A and B. Cells were harvested 2 days after transfection, fixed
with ethanol, and stained with propidium iodide, and their cell cycle distribution was determined by flow cytometry. Percentages of cells in S phase
are shown. The averages of the results from two independent experiments are shown as bar graphs.
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FIG. 7. Down-regulation of L23-induced cell cycle arrest is dependent on the function of p53. (A and B) Normal human fibroblast WI38 cells
and isogenic mutant WI38-E6 cells were transfected with either a control scrambled RNA duplex (siScr) or L23 siRNA (siL23) for 2 days, and cell
extracts were analyzed by Western blotting with the indicated antibodies. -HDM2, anti-HDM2; -p53, anti-p53; -p21, anti-p21; -L23, anti-L23;
-actin, anti-actin. (C and D) WI38 and WI38-E6 cells were transfected siRNA as described for panels A and B. Cells were harvested 2 days after
infection and stained with propidium iodide, and their cell cycle distribution was determined by flow cytometry. Percentages of cells in S phase are
shown. (E) Down-regulation of L23 releases nucleolar B23. U2OS cells were transfected with the indicated siRNA for 2 days. The cells were then
fixed and stained with a mouse anti-B23 (-B23) antibody (Zymed) and an fluorescein isothiocyanate-conjugated anti-mouse secondary antibody
(Jackson ImmunoResearch). Fluorescence images were captured with a cooled charge-coupled device color digital camera (model 2.2.0; Diag-
nostic) on an Olympus IX70 inverted microscope equipped with the appropriate fluorescence filters.
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FIG. 8. Inhibition of ribosomal biogenesis decreases the protein level of L23. (A) Low concentrations of actinomycin D induce p53-dependent
cell cycle arrest. U2OS cells were treated with the indicated concentrations of actinomycin D (Act D) for 24 h, and the cell lysates were analyzed
by Western blotting as described above. -HDM2, anti-HDM2; -p53, anti-p53; -L23, anti-L23; -actin, anti-actin. (B) Time required for actino-
mycin D treatment to suppress L23. U2OS cells were treated with 5 nM actinomycin D for the indicated times, and the protein levels were analyzed
as described above. (C) Inhibition of ribosomal biogenesis by 5 nM actinomycin D down-regulates L23 but not L11. U2OS cells were treated with
5 nM actinomycin D for 24 h before lysing, the cell lysates were resolved by SDS-PAGE, and Western blotting was performed as described above.
-L11, anti-L11. (D) Ectopic expression of L23 suppresses endogenous L23. U2OS cells were infected with the indicated viruses for 2 days, and
cell extracts were harvested and resolved by SDS-PAGE. The proteins were transferred onto a nitrocellulose membrane and blotted with the
indicated antibodies. -myc, anti-myc. (E) Suppression of endogenous L23 by ectopically expressed myc-L23 was independent of HDM2 and p53.
Normal human fibroblast WI38 cells were infected with the indicated viruses for 2 days. Cell extracts were harvested and resolved by SDS-PAGE,
and the proteins were analyzed as described above. , present; , absent.
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(13, 41). In this study we identified the interaction of the
ribosomal protein L23 with HDM2. L23-HDM2 interaction,
like the interaction of L11-HDM2 and ARF-HDM2, inhibits
the E3 ligase function of HDM2 and stabilizes and activates
p53. The evidences that HDM2 interacts with multiple ribo-
somal proteins suggest that the ribosomal protein-HDM2 in-
teraction may represent a link by which cells coordinate growth
with proliferation. It is presently unclear why multiple ribo-
somal proteins interact with HDM2. However, our evidence
suggests that multiple ribosomal proteins may sense different
growth inhibitory signals and may activate p53 through differ-
ent mechanisms. The distinctive responses of L23 and L11 to a
low level of actinomycin D treatment support this notion. The
multiple ribosomal proteins that interact with HDM2 could
also have a synergistic effect to bring about a quick and strong
inhibition of HDM2 when ribosomal damage occurs.
On the other hand, each of the HDM2-interacting ribosomal
proteins may transmit different ribosomal biogenesis signals to
the HDM2-p53 pathway so that multiple steps of ribosomal
biogenesis could be tightly monitored. Our data indicated that
the sites in HDM2 for L23 binding are different from those
required for L11 binding and that L23 and L11 can bind
HDM2 simultaneously to form a ternary complex (Fig. 3).
Independent interaction with HDM2 and an ability to form a
multi-ribosomal-protein–HDM2 complex support the notion
that the different HDM2-binding ribosomal proteins could act
independently to monitor different ribosomal stresses. Our
study showed that the endogenous L23 and L11 reacted dif-
ferently to actinomycin D treatment. We found that L23 dras-
tically decreases in response to 24 h of actinomycin D treat-
ment while the L11 level appears to be constant under the
same treatment (Fig. 8C). The basis of the difference is not yet
clear, but it further indicates that L23 and L11 react to differ-
ent ribosomal stresses and use different mechanisms to inhibit
HDM2. Ribosomal biogenesis is a highly coordinated process
involving many important cellular functions. It is conceivable
that perturbations of ribosomal function can occur at different
stages of ribosomal biogenesis, and each of the HDM2-inter-
acting ribosomal proteins may preferentially recognize a dif-
ferent ribosomal stress. This way, the cells ensure that the
entire ribosomal biogenesis pathway is correctly and efficiently
monitored. The two HDM2-binding ribosomal proteins, L11
and L23, clearly perform extraribosomal functions. There is
previous evidence that a number of ribosomal proteins have
secondary functions apart from both ribosome complex forma-
tion and protein synthesis, such as regulation of polymerase III
transcription by S20, participation in DNA repair by S3, reg-
ulation of development by L19, and tumor suppression by S6
(39).
Our data have shown that cells maintain a constant level of
L23 during growth. An abnormally high level of L23, such as
that provided by Ad-mediated expression, causes a p53-depen-
dent cell cycle arrest. An abnormally low level of L23, for
example, that generated by L23 siRNA, also causes a p53-
dependent cell cycle arrest. However, the mechanisms em-
ployed by an abnormally low level of L23 and an abnormally
high level of L23 to induce p53 appeared to be very different.
At a high level, the extra L23 interacts with and inhibits the E3
ligase function of HDM2 to stabilize and activate p53. At a low
level, it induces nucleolar stress and releases B23 (and perhaps
many other nucleolar components) into the nucleoplasm, and
the nucleoplasmic B23, in turn, can induce p53-dependent cell
cycle arrest (2, 27). We contemplate that one of the functions
of L23-HDM2 interaction could be to coordinate regulations
of cell growth and cell division. For example, DNA damage-
induced p53 activation could, on one hand, stop cell cycle
progression through activation of p21 and, on the other hand,
inhibit ribosomal biogenesis through activation of HDM2, and
the high level of HDM2 could take away newly synthesized L23
to inhibit ribosomal biogenesis.
Ribosomal biogenesis consumes a major part of the cell’s
energy and resources and plays a key role in the cell’s life cycle
(3, 20, 38). It is conceivable that the status of ribosomal bio-
genesis is constantly monitored in cells. Once abnormal activ-
ities of ribosomal function are detected and cells must stop
growth, it is necessary to transmit the signals to the cell cycle
regulators to simultaneously stop proliferation. The tumor sup-
pressor p53, as it does in many other circumstances of cellular
stress, plays a key role in integrating ribosomal stress signals
and transmitting them to the cell cycle regulators. The involve-
ment of p53 in the monitoring of ribosomal biogenesis has
been shown in an early study in which depletion of ribonucle-
otide pools induces a p53-dependent cell cycle arrest that does
not involve DNA damage (12). In a recent study, functional
inactivation of Bop1, a nucleolar protein involved in rRNA
processing and ribosomal assembly, led to a p53-dependent
cell cycle arrest (25). Although unclear about the molecular
mechanisms, these studies have demonstrated that, in multi-
cellular higher-order organisms, the ribosome status is contin-
uously monitored by thus far unknown mechanisms that in-
volve the function of p53. The interaction of HDM2 with
multiple ribosomal proteins provides a potential link between
ribosomal biogenesis and p53 function, so the disturbance of
ribosomal function can impinge on cell cycle progression.
The involvement of ribosomal proteins in regulating p53
function rekindles interest in the possibility that some ribo-
somal proteins may act as tumor suppressors. Considering the
abundance of ribosomal proteins in proliferating cells, it is
likely that a proportion of these proteins participate in extrari-
bosomal functions (18). Previous studies have shown that de-
regulated expression of ribosomal proteins induces cell cycle
arrest and apoptosis (19, 21). These studies suggest that, when
not participating in the translational machinery, the ribosomal
proteins may contribute to other cellular functions. It is tempt-
ing to postulate that the interaction of ribosomal proteins with
the HDM2-p53 pathway constitutes a surveillance system,
which may have developed during evolution, to safeguard the
integrity of ribosomal biogenesis in higher-order eukaryotic
cells and to coordinate growth with proliferation. In this
regard, the idea that mutations either in the ribosomal pro-
tein genes (e.g., L11 or L23) or in HDM2 that prohibit their
interaction could have developed in certain human cancers
seems not too far fetched and deserves to be further ex-
plored.
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